Antimetastatic effect of flurbiprofen and other platelet aggregation inhibitors.
In the present study, we have examined the antimetastatic effect of flurbiprofen, a nonsteroidal antiinflammatory drug, on spontaneous metastases formation in mice bearing Lewis lung carcinoma and these results were compared with effects of other inhibitors of platelet function (mopidamole, dipyridamole, pentoxifylline). Flurbiprofen decreased significantly spontaneous metastases formation in a dose-depending manner. From the results obtained, it appears that the treatment with flurbiprofen, either on days 1-8 or days 1-21, was similarly effective. In mopidamole treated groups the number of animals with lung metastases was significantly decreased. This effect was not observed after treatment with dipyridamole or pentoxifylline.
D000818:Animals; D000970:Antineoplastic Agents; D004176:Dipyridamole / Q000627:therapeutic use*; D005480:Flurbiprofen / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009012:Mopidamol / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D010431:Pentoxifylline / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects; D011422:Propionates / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013805:Theobromine / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D011422:Propionates; D011743:Pyrimidines; D009012:Mopidamol; D005480:Flurbiprofen; D004176:Dipyridamole; D013805:Theobromine; D010431:Pentoxifylline